The Quantellect read.As of Nov 19, 2026, 7 active firms cover Inhibikase Therapeutics Inc: 6 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $1.50 to $8.00 (about 5.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $4.75 sits 242% above the current $1.39. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy686%
Neutral114%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$4.75
+241.7% upside
Average target across 6 active firms as of Nov 19, 2026 vs $1.39 current
Highest Target$8.00
Average Target$4.75
Lowest Target$1.50
Detailed analyst forecasts for IKT
Showing 1–5 of 5 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 6 of 7 active firms rate IKT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IKT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.12 – $-0.09 · 2 analysts
Next period, 2 analysts expect Inhibikase Therapeutics Inc to earn $-0.10 a share (range $-0.12 – $-0.09), versus — a year earlier. Full-year consensus is $-0.40, growing to $-0.41 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Inhibikase Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IKT.
#1
EW
Edward White
HC Wainwright & Co. · Rank #376
Neutral
No targeton IKT
Overall win rate
31%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$8.00+475.5% to target
Overall win rate
36%
+ Follow
#3
Aydin Huseynov
Ladenburg Thalmann · Rank #564
Buy
$4.00+187.8% to target
Overall win rate
32%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #567
Buy
$8.00+475.5% to target
Overall win rate
30%
+ Follow
#5
RS
Ram Selvaraju
H.C. Wainwright
Buy
$8.00+475.5% to target
Coverage
—
+ Follow
IKT stock forecast FAQ
What is IKT's average 12-month price target?+
The 6 active firms with a live target average $4.75 for Inhibikase Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $1.50 low, as of Nov 19, 2026.
Is IKT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IKT?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $1.50 (Chardan Capital). The average of all 6 active-firm targets is $4.75.
How many active Wall Street firms cover IKT?+
7 active firms have a recognized rating on Inhibikase Therapeutics Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IKT?+
Among analysts who currently cover IKT, Edward White of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #376). Their current call is Neutral.
What is Inhibikase Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.12 – $-0.09) across 2 analysts. Full-year EPS is projected at $-0.40, rising to $-0.41 the following year.
How much revenue is Inhibikase Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading IKT lately?+
As of Nov 19, 2026, 6 of 7 active firms rate IKT a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.